How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
RNA Sequencing Service Market
- By Sequencing Type: Whole Transcriptome Sequencing, Targeted RNA Sequencing, Single-cell RNA Sequencing, Small RNA Sequencing, Strand-specific RNA Sequencing
- By Application: Gene Expression Analysis, Biomarker Discovery, Drug Development and Toxicology, Disease Research, Agricultural Research
- By End User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Clinical Research Organizations, Hospitals and Diagnostic Laboratories, Agricultural and Environmental Research Centers
- By Service Model: In-house Sequencing Services, Outsourced Sequencing Services, Custom RNA Sequencing Solutions, Data Analysis and Bioinformatics Services
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Whole Transcriptome Sequencing leads By Sequencing Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 279 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.168 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.176 →
Full report · locked preview
Everything inside the RNA Sequencing Service Market report
A complete, evidence-based study - 11 chapters and 117 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Sequencing Type 5
Application 5
End User 5
Service Model 4
Companies profiled
Illumina Inc.
Thermo Fisher Scientific Inc.
BGI Genomics
Novogene Corporation
Macrogen Inc.
Eurofins Scientific
Q2 Solutions
Genewiz (Azenta Life Sciences)
Genoox
Personalis Inc.
ArcherDX (acquired by Invitae)
CeGaT GmbH
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Illumina Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Thermo Fisher Scientific Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →BGI Genomics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Novogene Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Macrogen Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Eurofins Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Q2 Solutions
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Genewiz (Azenta Life Sciences)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Genoox
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Personalis Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →ArcherDX (acquired by Invitae)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →CeGaT GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Novartis Institutes for BioMedical Research
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Fulgent Genetics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Sema4
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,385M by 2033 · 5.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Whole Transcriptome Sequencing50.7
- Targeted RNA Sequencing10.6
- Single-cell RNA Sequencing13.2
- Small RNA Sequencing9.2
- Strand-specific RNA Sequencing16.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,363M → $2,095M · 5.5%
Europe$950.3M → $1,462M · 5.5%
Asia Pacific$867.6M → $1,303M · 5.2%
Latin America$537.1M → $798.3M · 5.1%
Middle East and Africa$413.2M → $609.3M · 5.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.552026
5.552027
5.572028
5.582029
5.592030
5.602031
5.612032
5.642033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Illumina Inc.19.7
- Thermo Fisher Scientific Inc.17.6
- BGI Genomics11.3
- Novogene Corporation7.8
- Macrogen Inc.11.9
- Eurofins Scientific3.6
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Sequencing Type21.4%
Application17.6%
End User27.8%
Service Model33.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.4
- Europe23.3
- Asia Pacific20.8
- Latin America12.7
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Illumina Inc. | 74 | 93 | 73 | 92 | 92 | 87 | 85 |
| Thermo Fisher Scientific Inc. | 81 | 75 | 91 | 86 | 79 | 80 | 82 |
| BGI Genomics | 66 | 70 | 63 | 63 | 74 | 72 | 68 |
| Novogene Corporation | 72 | 73 | 72 | 66 | 67 | 73 | 71 |
| Macrogen Inc. | 64 | 63 | 56 | 56 | 54 | 53 | 58 |
| Eurofins Scientific | 56 | 56 | 52 | 48 | 51 | 71 | 56 |
| Q2 Solutions | 65 | 58 | 65 | 61 | 62 | 66 | 63 |
| Genewiz (Azenta Life Sciences) | 49 | 51 | 42 | 46 | 39 | 46 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Illumina Inc.
- Thermo Fisher Scientific Inc.
- BGI Genomics
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Illumina Inc. | ✓ | ◐ | ✓ | ◐ | ✓ | ✓ |
| Thermo Fisher Scientific Inc. | ✓ | ◐ | ✓ | ◐ | ◐ | ◐ |
| BGI Genomics | − | ◐ | ◐ | ✓ | ✓ | ◐ |
| Novogene Corporation | ✓ | ◐ | ◐ | ◐ | − | ◐ |
| Macrogen Inc. | − | − | − | ◐ | ◐ | − |
| Eurofins Scientific | ◐ | ◐ | − | ◐ | − | ◐ |
| Q2 Solutions | − | − | − | − | ◐ | ◐ |
| Genewiz (Azenta Life Sciences) | − | ◐ | − | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Illumina Inc.85
2Thermo Fisher Scientific Inc.82
3Novogene Corporation71
4BGI Genomics68
5Q2 Solutions63
6Macrogen Inc.58
7Eurofins Scientific56
8Genewiz (Azenta Life Sciences)46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Illumina Inc.Thermo Fisher Scientific Inc.
Challenger2
Strong scale, closing on the leaders.
BGI GenomicsNovogene Corporation
Contender2
Focused players with pockets of strength.
Macrogen Inc.Q2 Solutions
Niche2
Specialists in a single segment or region.
Eurofins ScientificGenewiz (Azenta Life Sciences)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Sequencing Type in North America, then scale across RNA Sequencing Service Market — a $70M beachhead inside a $1.03B market.
Beachhead (SOM)$70Mobtainable near-term
Serviceable (SAM)$413Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Whole Transcriptome Sequencing
Best fit — highest urgency & budget in Sequencing Type.
Economic buyer77 fit
Targeted RNA Sequencing
Strong fit — clear ROI and a fast path to value.
End user69 fit
Single-cell RNA Sequencing
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Sequencing Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales41%
Partner / channel30%
Digital / self-serve22%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Sequencing Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win RNA Sequencing Service Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified22%
Evaluation12%
Closed-won5%
$19.7KCAC
$83KLTV
4.2:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
RNA Sequencing Service Market is a high-growth opportunity — $9.12B by 2033, compounding at 11.1%.
TAM · 2025$3.92Btoday
TAM · 2033$9.12Bforecast
CAGR11.1%2027–2033
Cumulative$55.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.12BTotal addressable market
SAM$3.56BServiceable available market
SOM$772MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.1% CAGR
Demand compounds through 2033, outpacing GDP across Sequencing Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Sequencing Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.12BLarge & growingTAM by 2033 at 11.1% CAGR
$3.56BServiceable nowreachable with today’s model
$772MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.11BBear7.2% CAGR
$9.12BBase11.1% CAGR
$11.7BBull14.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
RNA Sequencing Service Market — a $10.9B market by 2033. Plan: grow share from 8.8% to 18.3%.
Market size · 2033$10.9Btotal addressable
Market CAGR11.4%2027–2033
Target share18.3%from 8.8% today
Revenue ambition$1.99Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.8% | 18.3% | On track |
| Revenue | $984M | $1.99B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 37.3% | 42.3% | Behind |
| Customer retention | 89.5% | 96.6% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Sequencing Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Sequencing Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $215M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Sequencing Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the RNA Sequencing Service Market conversation — a $6.60B market you can size, segment and defend in minutes.
Market size · 2033$6.60Btotal opportunity
Growth5.2%CAGR to 2033
Addressable buyers1,459+accounts in scope
Typical ROI4.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Sequencing Type
Goal Grow share in Sequencing Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.8×return on cost, year one
< 3 mopayback period
$69K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Illumina Inc.Thermo Fisher Scientific Inc.BGI GenomicsNovogene CorporationMacrogen Inc.Eurofins ScientificQ2 SolutionsGenewiz (Azenta Life Sciences)+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your RNA Sequencing Service Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
RNA Sequencing Service Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Chromatography Based Cannabis Analysis Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportHorse Management Software Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportMedication Pouch Inspection Systems Market
Market size, share, segmentation and regional forecast.
$523M market · 2025 base year
View reportMedical Device Complaint Management Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportCold Chain Tracking and Monitoring Systems Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportDecision-support System (DSS) Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportAcoustic Wave Technology Biosensors Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportAcoustic Wave Sensors in Biology Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportAcoustic Wave Biosensors Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportAcoustic Sound Imaging Camera Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportAcoustic Respiration Sensor Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportAcoustic Neuroma Treatment Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.